CBS 2019
CBSMD教育中心
English

急性冠脉综合征

科研文章

荐读文献

Late Survival Benefit of Percutaneous Coronary Intervention Compared With Medical Therapy in Patients With Coronary Chronic Total Occlusion: A 10-Year Follow-Up Study Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study Long-Term Follow-Up of Complete Versus Lesion-Only Revascularization in STEMI and Multivessel Disease: The CvLPRIT Trial Canadian SCAD Cohort Study: Shedding Light on SCAD From a United Front Treating Multivessel Coronary Artery Disease in ST-Segment Elevation Myocardial Infarction: Why, How, and When? Spontaneous Coronary Artery Dissection: Current State of the Science: A Scientific Statement From the American Heart Association Utility and Challenges of an Early Invasive Strategy in Patients Resuscitated From Out-of-Hospital Cardiac Arrest Another Nail in the Coffin for Intra-Aortic Balloon Counterpulsion in Acute Myocardial Infarction With Cardiogenic Shock Global Chronic Total Occlusion Crossing Algorithm: JACC State-of-the-Art Review Systems of Care for ST-Segment–Elevation Myocardial Infarction: A Policy Statement From the American Heart Association

Original Research2021 Mar 9.

JOURNAL:Diabetes Obes Metab. Article Link

Red Cell Distribution Width in Patients with Diabetes and Myocardial Infarction: an analysis from the EXAMINE trial

JP Ferreira, Z Lamiral, G Bakris et al. Keywords: alogliptin; outcomes; red cell distribution width; T2DM

ABSTRACT

BACKGROUND - Red blood cell distribution width (RDW) is a measure of size variability in the red blood cell population (anisocytosis). Increased RDW may arise from any condition that affects erythropoiesis or the survival of erythrocytes. RDW has been associated with poor prognosis in patients with type 2 diabetes (T2D). Whether RDW is a risk marker for adverse cardiovascular outcomes or also a marker of noncardiovascular health concerns is of clinical importance.

 

AIMS - To determine the clinical correlates of increased RDW, its potential mechanistic association with multiple circulating biomarkers, and its prognostic value, in patients with (T2D) who had a recent acute coronary syndrome.

 

METHODS - We used timeupdated Cox models applied to patients enrolled in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial.

 

RESULTS - A total of 5380 patients were included, the median age was 61 years and 32% were women. Patients with higher RDW were older, more frequently women, with longer duration of diabetes duration, and increased comorbidities. An RDW >16.1% (both baseline and timeupdated) was independently associated with the study primary composite outcome of nonfatal myocardial infarction, nonfatal stroke or cardiovascular death (timeupdated adjusted HR =1.36, 95%CI =1.161.61, p < 0.001), allcause death (timeupdated adjusted HR =2.01, 95%CI =1.602.53, p < 0.001), as well as mortality from nonCV causes (timeupdated adjusted HR =2.67, 95%CI =1.724.15, p < 0.001). RDW had a weaktomoderate correlation with hemoglobin and circulating markers that reflected inflammation, apoptosis, fibrosis and congestion. Alogliptin did not alter RDW values.

 

CONCLUSIONS - RDW is a marker of disease severity associated with a multitude of poor outcomes, including both cardiovascular and noncardiovascular death. RDW correlated modestly with inflammatory, proapoptotic, profibrotic, and congestion markers, and its levels were not affected by alogliptin during the course of the trial.

 

This article is protected by copyright. All rights reserved.